Published in Ther Adv Vaccines on January 01, 2014
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Biomaterials for mRNA delivery. Biomater Sci (2015) 0.87
Specific in vivo knockdown of protein function by intrabodies. MAbs (2015) 0.80
Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. Expert Rev Vaccines (2015) 0.79
Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials (2017) 0.76
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther (2017) 0.75
Single domain antibodies for the knockdown of cytosolic and nuclear proteins. Protein Sci (2017) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 71.50
Cancer genome landscapes. Science (2013) 25.33
RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science (2006) 16.00
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol (2003) 11.48
Direct gene transfer into mouse muscle in vivo. Science (1990) 10.39
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14
Direct cell reprogramming is a stochastic process amenable to acceleration. Nature (2009) 8.71
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
5'-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol Rev (1980) 6.14
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature (2005) 5.32
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 5.30
Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity (2005) 5.23
Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science (1989) 4.84
IgE in allergy and asthma today. Nat Rev Immunol (2008) 4.67
Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol (2006) 4.53
T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol (2008) 4.52
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol (2005) 4.01
How the messenger got its tail: addition of poly(A) in the nucleus. Trends Biochem Sci (1990) 3.92
CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol (2007) 3.87
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
DC-based cancer vaccines. J Clin Invest (2007) 3.81
RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell (2010) 3.59
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med (1996) 3.01
Activation of innate immunity is required for efficient nuclear reprogramming. Cell (2012) 2.99
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther (2008) 2.50
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol (2012) 2.48
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol (2011) 2.43
DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med (2011) 2.41
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev (2001) 2.23
Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol (1998) 2.20
Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol (2013) 2.11
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis (2012) 2.08
Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol (1996) 2.01
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother (2011) 2.01
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood (2006) 2.00
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood (2004) 1.84
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84
IL-5 and eosinophilia. Curr Opin Immunol (2008) 1.79
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol (2002) 1.76
Emerging clinical applications of RNA. Nature (2002) 1.76
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol (2013) 1.67
Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev (2004) 1.66
Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun (2010) 1.64
Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther (2012) 1.61
Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med (2003) 1.59
DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol (1998) 1.57
In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol (2000) 1.53
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol (2012) 1.49
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (2009) 1.44
Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res (2003) 1.44
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res (2010) 1.42
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother (2008) 1.40
Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel (2007) 1.39
Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol (2004) 1.38
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res (2010) 1.38
Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat Protoc (2013) 1.36
Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res (2000) 1.35
Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc Natl Acad Sci U S A (2010) 1.33
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res (1995) 1.30
Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine (1994) 1.30
Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol (1993) 1.29
Toll-like receptor 7 is required for effective adaptive immune responses that prevent persistent virus infection. Cell Host Microbe (2012) 1.29
A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res (1995) 1.20
Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther (2008) 1.19
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res (2012) 1.18
Messenger RNA-based vaccines. Expert Opin Biol Ther (2004) 1.18
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res (2011) 1.17
Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol (2011) 1.15
Innate and adaptive immune responses to viral infection and vaccination. Curr Opin Virol (2011) 1.15
Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol (2002) 1.14
Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther (2010) 1.14
Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother (2011) 1.11
Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol (2010) 1.11
Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 1.09
RNA-based vaccines. Vaccine (2012) 1.08
Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol (2008) 1.08
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis (2001) 1.07
Reshaping the Bet v 1 fold modulates T(H) polarization. J Allergy Clin Immunol (2011) 1.05
Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther (2012) 1.05
Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol (2005) 1.05
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med (2012) 1.04
Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect (2013) 1.04